CATT Trial Results

In this edition of Retina 360, the panel will discuss the results of the newly released Comparison of Age-related Macular Degeneration Treatment Trails (CATT). Revisiting the debate of using FDA approved treatments versus off-label; the panel describes benefits of both Lucentis™ and Avastin™ and how they are prescribed in their practice setting. The panel will also discuss treatment intervals based on the treatment decision.

Posted: 6/06/2011